Skip to content
Anuh Pharma logo

Anuh Pharma

ANUHPHR NSE
₹79.61 0.46 (0.58%)
Market Cap
₹798 Cr
P/E
18.05

Anuh Pharma (ANUHPHR) share price was ₹79.61 at the 28 Oct 2026 close; market capitalisation ₹798 Cr; P/E (TTM) 18.05; sector Healthcare. The share price fell 11.9% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 3.9% year on year to ₹193.8 Cr and net profit was ₹11 Cr, against ₹8 Cr a year earlier (compared with Jun 2025). Promoters held 71.80% of Anuh Pharma in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 53/100 (Average) as of 28 Oct 2026.

Close 28 Oct 2026 ₹79.61 −10.00 −11.16% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹798 Cr
P/E (TTM)
18.05
EBITDA
₹66.10 Cr
Return on Equity
11.65%
Debt to Equity
0
Book Value
₹35.14
EPS (TTM)
₹4.41
52W High
₹99.50
52W Low
₹67.00

Price-based figures as of 28 Oct 2026, 15:31 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Anuh Pharma (this company)
₹79.6118.05798 Cr2.271.90%11.65%15.43%784 Cr44 Cr
Median 8 companies₹1,561.5534.731,17,574 Cr4.690.72%12.98%16.69%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
53 Average
Overall score
Data confidence 100/100

Category scores

Quality Weak 42
Returns, margins, earnings quality 22%
Valuation Strong 74
Cheap vs sector & own history 24%
Growth Poor 36
Sales & profit trajectory 9%
Financial Health Strong 71
Solvency, leverage, coverage 9%
Momentum Poor 34
Trend strength, vol-adjusted 12%
Ownership Good 55
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 24.4%

Weaknesses

1
  • Company has a low return on equity of 13.8% over last 3 years.

Technical Indicators

Oscillators

BearishNeutralBullish

Bearish

Bearish
2
Neutral
7
Bullish
0

Overall

BearishNeutralBullish

Bearish

Bearish
11
Neutral
7
Bullish
1

Moving Averages

BearishNeutralBullish

Bearish

Bearish
9
Neutral
0
Bullish
1

Growth Rate

Revenue Growth
15.65% higher than 3Y

change over 1 year

Net Income Growth
-13.5% lower than 3Y

change over 1 year

Cash Flow Change
-108%

change over 1 year

EBITDA Margin Change
-18.88%

change over 1 year Operating margin 8% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
161
150
172
164
138
166
160
198
186
186
197
202
194
Expenses
148
132
148
145
127
149
145
179
176
174
178
182
178
Operating Profit
14
18
24
19
11
17
15
19
10
12
19
20
16
OPM %
9%
12%
14%
12%
8%
10%
9%
9%
6%
6%
10%
10%
8%
Other Income
3
2
4
3
4
3
1
1
3
1
2
-1
3
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
2
2
2
2
2
2
2
3
3
3
3
3
2
PBT
15
18
25
20
12
18
13
17
11
10
18
16
17
Tax %
24%
23%
24%
22%
22%
17%
22%
28%
24%
23%
25%
25%
32%
Net Profit
12
14
19
15
10
15
10
12
8
8
13
12
11
EPS (₹)
1.17
1.38
1.91
1.53
0.95
1.5
1.03
1.24
0.83
0.76
1.34
1.17
1.14
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
284
326
206
238
321
307
432
487
527
647
662
772
779
Expenses
253
289
183
220
291
284
387
439
476
571
600
709
712
Operating Profit
31
38
23
18
30
23
45
47
52
76
62
62
67
OPM %
11%
12%
11%
8%
9%
8%
10%
10%
10%
12%
9%
8%
9%
Other Income
5
4
8
7
5
4
11
5
6
12
9
4
5
Interest
1
1
1
0
1
1
2
2
1
1
1
1
0
Depreciation
3
2
2
2
2
7
15
12
10
9
9
11
11
PBT
32
38
28
23
32
19
39
39
47
78
61
54
60
Tax %
31%
32%
27%
29%
28%
25%
26%
22%
24%
23%
22%
24%
—
Net Profit
22
26
20
17
23
14
28
31
36
60
47
41
44
EPS (₹)
2.19
2.57
2
1.65
2.33
1.43
2.84
3.05
3.61
5.99
4.73
4.1
4.41
Div. Payout %
27%
24%
31%
42%
29%
48%
26%
29%
28%
21%
16%
37%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
4
13
13
13
13
13
25
25
25
25
25
50
Reserves
97
107
128
137
152
150
166
189
216
266
301
302
Borrowings
0
2
0
2
4
45
14
4
1
3
11
0
Other Liabilities
67
71
48
57
71
119
128
129
163
152
170
205
Total Liabilities
168
193
189
209
240
326
333
347
405
446
507
557
Fixed Assets
9
18
17
17
21
84
71
61
53
49
58
57
CWIP
0
0
0
6
34
0
0
0
0
0
0
0
Investments
43
43
70
66
39
80
31
43
91
97
106
84
Other Assets
116
131
101
120
147
163
230
243
261
300
342
416
Total Assets
168
193
189
209
240
326
333
347
405
446
507
557
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
19
16
26
2
7
49
-19
29
54
13
37
-3
Investing
-12
-5
-20
2
3
-77
52
-8
-43
1
-20
18
Financing
-8
-9
-4
-5
-7
22
-33
-19
-12
-9
-5
-26
Net Cash Flow
-1
2
2
-1
3
-5
0
2
-2
5
12
-12
Free Cash Flow
18
6
25
-5
-22
13
-25
27
52
8
17
-11
CFO/EBITDA
96
78
149
49
56
232
-20
80
130
42
78
16
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
88
84
100
109
85
96
90
102
118
107
119
113
Inventory Days
27
35
72
64
64
98
90
77
66
57
54
90
Days Payable
79
77
102
105
89
166
133
117
139
105
115
114
Cash Conversion Cycle
36
42
70
68
61
28
48
62
46
58
59
89
Working Capital Days
43
48
79
80
65
-10
57
68
61
69
68
92
ROCE %
33%
35%
19%
14%
19%
10%
16%
18%
19%
26%
17%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Anuh Pharma insights

63 extracted metrics + investor summaries across FY05–FY27.

Shareholding Pattern

FIIs0.11%Promot.71.80%Others4.92%Public23.17%As ofSep 2026

Documents

1
Concall - Aug 2026 Aug 2026
2
Concall - May 2026 May 2026
3
Concall - Feb 2026 Feb 2026
4
Concall - Nov 2025 Nov 2025
5
Concall - Aug 2025 Aug 2025

Frequently Asked Questions about Anuh Pharma

What does Anuh Pharma Ltd do?
Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals[1]
Where is Anuh Pharma Ltd (ANUHPHR) listed?
Anuh Pharma Ltd trades as ANUHPHR on the NSE and under code 506260 on the BSE.
Which sector does Anuh Pharma Ltd belong to?
Anuh Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Anuh Pharma Ltd?
Anuh Pharma Ltd has a market capitalisation of ₹797.88 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Anuh Pharma Ltd?
Anuh Pharma Ltd trades at a PE ratio of 18.05 as of 28 Oct 2026, on earnings per share of ₹4.41, against a book value of ₹35.14 per share.
What is the 52-week high and low of Anuh Pharma Ltd?
Over the last 52 weeks Anuh Pharma Ltd has traded between ₹67 and ₹99.5 as of 28 Oct 2026.
Does Anuh Pharma Ltd pay dividends?
Anuh Pharma Ltd has a dividend yield of 1.90%.
What is the Return on Equity (ROE) of Anuh Pharma Ltd?
Anuh Pharma Ltd reported a return on equity of 11.65%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals[1]

Website anuhpharma.com
CEO Mr. Ritesh Bipin Shah MBA
Employees 295
Listed 2008-01-02
Face Value ₹ 5
Shares Outstanding 10,02,24,000

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ANUHPHR.md for Anuh Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month